S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Urgent Warning (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Urgent Warning (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
3 Secrets To Consistent Trading Success (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Urgent Warning (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Urgent Warning (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
3 Secrets To Consistent Trading Success (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Urgent Warning (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Urgent Warning (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
3 Secrets To Consistent Trading Success (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
Urgent Warning (Ad)
Intensity and insults rise as lawmakers debate debt ceiling
UK travelers face hours-long waits for ferries to France
Urgent Warning (Ad)
Credit Suisse takeover hits heart of Swiss banking, identity
Small areas reopen near Fukushima nuclear plant, few return
3 Secrets To Consistent Trading Success (Ad)pixel
UN food chief: Billions needed to avert unrest, starvation
'War of the states': EV, chip makers lavished with subsidies
NASDAQ:RETA

Reata Pharmaceuticals - RETA Short Interest Ratio & Short Volume

$90.92
+0.90 (+1.00%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$88.01
$93.16
50-Day Range
$30.85
$93.17
52-Week Range
$18.47
$95.00
Volume
851,682 shs
Average Volume
1.13 million shs
Market Capitalization
$3.34 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$96.89

Reata Pharmaceuticals Short Interest Data

Current Short Volume
5,030,000 shares
Previous Short Volume
8,360,000 shares
Change Vs. Previous Month
-39.83%
Dollar Volume Sold Short
$434.74 million
Short Interest Ratio / Days to Cover
3.5
Last Record Date
March 15, 2023
Outstanding Shares
36,730,000 shares
Float Size
27,820,000 shares
Short Percent of Float
18.08%
Today's Trading Volume
851,682 shares
Average Trading Volume
1,127,790 shares
Today's Volume Vs. Average
-24.48%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Reata Pharmaceuticals ?

Sign up to receive the latest short interest report for Reata Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

RETA Short Interest Over Time

RETA Days to Cover Over Time

RETA Percentage of Float Shorted Over Time

Reata Pharmaceuticals (NASDAQ:RETA) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
3/15/20235,030,000 shares $434.74 million -39.8%18.1%3.5 $86.43
2/28/20238,360,000 shares $260.58 million -5.3%30.4%6.1 $31.17
2/15/20238,830,000 shares $375.28 million +5.0%32.1%10.2 $42.50
1/31/20238,410,000 shares $364.41 million +3.3%30.4%13.7 $43.33
1/15/20238,140,000 shares $310.79 million +2.0%29.4%13.8 $38.18
12/30/20227,980,000 shares $303.16 million +9.0%28.8%11.3 $37.99
12/15/20227,320,000 shares $254.30 million -8.0%26.1%10.4 $34.74
11/30/20227,960,000 shares $315.06 million +9.2%28.4%10.7 $39.58
11/15/20227,290,000 shares $303.77 million +10.0%26.0%8.1 $41.67
10/31/20226,630,000 shares $213.49 million +24.2%23.8%6.8 $32.20
10/15/20225,340,000 shares $161.32 million +3.9%18.6%5.5 $30.21
9/30/20225,140,000 shares $129.17 million +3.8%17.9%6.6 $25.13
9/15/20224,950,000 shares $142.31 million +18.4%17.3%6.5 $28.75
8/31/20224,180,000 shares $99.94 million -11.3%14.6%5.6 $23.91
8/15/20224,710,000 shares $97.07 million -6.7%16.4%8.2 $20.61
7/31/20225,050,000 shares $154.93 million +0.4%17.5%10.3 $30.68
7/15/20225,030,000 shares $179.22 million +0.2%17.5%11.6 $35.63
6/30/20225,020,000 shares $152.56 million +2.0%17.4%10.7 $30.39
6/15/20224,920,000 shares $153.70 million +5.4%17.7%8.1 $31.24
5/31/20224,670,000 shares $132.07 million -6.6%16.8%7.7 $28.28
5/15/20225,000,000 shares $122.70 million -1.6%18.0%7.6 $24.54
4/30/20225,080,000 shares $128.93 million +10.7%17.1%7.6 $25.38
4/15/20224,590,000 shares $156.56 million +21.1%15.4%6.8 $34.11
3/31/20223,790,000 shares $124.16 million +11.8%12.8%5.4 $32.76
3/15/20223,390,000 shares $108.11 million +40.1%11.4%5.3 $31.89
2/28/20222,420,000 shares $79.23 million -3.2%8.2%2.4 $32.74
2/15/20222,500,000 shares $66.88 million -15.3%8.4%2.7 $26.75
1/31/20222,950,000 shares $82.95 million -23.6%10.0%3.2 $28.12
1/15/20223,860,000 shares $110.94 million -9.0%13.1%4.5 $28.74
12/31/20214,240,000 shares $111.81 million -2.3%14.4%5.6 $26.37
12/15/20214,340,000 shares $127.21 million -9.8%14.7%6.3 $29.31
11/30/20214,810,000 shares $411.74 million +14.0%16.2%9.5 $85.60
11/15/20214,220,000 shares $403.81 million +1.9%14.2%19.7 $95.69
10/29/20214,140,000 shares $397.48 million +1.5%13.9%17 $96.01
10/15/20214,080,000 shares $401.64 million +4.4%13.7%16.8 $98.44
9/30/20213,910,000 shares $393.39 million -0.3%13.2%15.4 $100.61
9/15/20213,920,000 shares $415.72 million -3.0%13.2%12.1 $106.05
8/31/20214,040,000 shares $430.30 million -3.6%13.6%11.6 $106.51
8/13/20214,190,000 shares $445.31 million +11.7%14.2%10.1 $106.28
7/30/20213,750,000 shares $469.91 million +1.1%12.7%8 $125.31













RETA Short Interest - Frequently Asked Questions

What is Reata Pharmaceuticals' current short interest?

Short interest is the volume of Reata Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 15th, investors have sold 5,030,000 shares of RETA short. 18.08% of Reata Pharmaceuticals' shares are currently sold short. Learn More on Reata Pharmaceuticals' current short interest.

What is a good short interest ratio for Reata Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RETA shares currently have a short interest ratio of 4.0. Learn More on Reata Pharmaceuticals's short interest ratio.

Which institutional investors are shorting Reata Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Reata Pharmaceuticals: Jane Street Group LLC, Belvedere Trading LLC, Boothbay Fund Management LLC, Susquehanna International Group LLP, Group One Trading L.P., Cutler Group LLC CA, Simplex Trading LLC, and Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Reata Pharmaceuticals?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 18.08% of Reata Pharmaceuticals' floating shares are currently sold short.

Is Reata Pharmaceuticals' short interest increasing or decreasing?

Reata Pharmaceuticals saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 5,030,000 shares, a drop of 39.8% from the previous total of 8,360,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Reata Pharmaceuticals' float size?

Reata Pharmaceuticals currently has issued a total of 36,730,000 shares. Some of Reata Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Reata Pharmaceuticals currently has a public float of 27,820,000 shares.

How does Reata Pharmaceuticals' short interest compare to its competitors?

18.08% of Reata Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Reata Pharmaceuticals: IVERIC bio, Inc. (7.06%), Zai Lab Limited (3.33%), Amicus Therapeutics, Inc. (7.39%), Maravai LifeSciences Holdings, Inc. (4.45%), ACADIA Pharmaceuticals Inc. (5.31%), PTC Therapeutics, Inc. (7.38%), Bausch Health Companies Inc. (7.65%), Ultragenyx Pharmaceutical Inc. (4.58%), Cerevel Therapeutics Holdings, Inc. (7.84%), and Axsome Therapeutics, Inc. (24.83%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($3.66 billion), Occidental Petroleum Co. ($2.62 billion), Coinbase Global, Inc. ($2.38 billion), T. Rowe Price Group, Inc. ($2.13 billion), Verisk Analytics, Inc. ($2.08 billion), Snowflake Inc. ($1.95 billion), Paramount Global ($1.78 billion), Etsy, Inc. ($1.60 billion), Teck Resources Limited ($1.51 billion), and Voya Financial, Inc. ($1.49 billion). View all of the most shorted stocks.

What does it mean to sell short Reata Pharmaceuticals stock?

Short selling RETA is an investing strategy that aims to generate trading profit from Reata Pharmaceuticals as its price is falling. RETA shares are trading up $0.90 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Reata Pharmaceuticals?

A short squeeze for Reata Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RETA, which in turn drives the price of the stock up even further.

How often is Reata Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RETA, twice per month. The most recent reporting period available is March, 15 2023.



This page (NASDAQ:RETA) was last updated on 4/1/2023 by MarketBeat.com Staff